Delivery Order SPE2DB24D2109-SPE2DB25FHXVF
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order on September 2, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply RINVOQ ER 30 mg tablets in quantities of 30-unit packages. The contract is valued at $7,943.17 with a firm fixed price structure and an ultimate completion date of September 3, 2025. This is a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order contract from the Defense Logistics Agency (DLA) on September 18, 2025, valued at $16,823.38 for RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order was competitively awarded with no set-aside designation and carries an ultimate completion date of September 19, 2025. The award is issued as a child contract under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $101,921.94 by the Defense Logistics Agency on August 12, 2025, with an ultimate completion date of August 13, 2025. The contract, awarded under firm fixed price terms with no set-aside designation, covers the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This delivery order is a child contract under AmerisourceBergen's significant...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $9,334.98 by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30s. The contract is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and was competitively awarded with no set-aside designation. This award represents a child contract under AmerisourceBergen's broader relationship...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at approximately $6,000 by the Defense Logistics Agency (DLA) on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract, awarded under firm fixed pricing with no set-aside designation, calls for the delivery of RINVOQ ER 15 mg tablets in a 30-count unit dosage. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 30, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose) valued at $11,415.23. This firm fixed-price contract award was competitively procured with no set-aside designation and carries an ultimate completion date of July 31, 2025. The delivery order is funded through the Defense Logistics Agency's Medical Supply Chain, which procures...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- AmerisourceBergen Drug Corp was awarded a Delivery Order contract by the Defense Logistics Agency (DLA) on August 5, 2025, for the supply of RINVOQ ER 15 MG tablets in quantities of 30 units. This firm fixed price delivery order, valued at $11,576.19, represents a non-competitive award under DLA's pharmaceutical supply chain supporting federal medical procurement needs. The contract is scheduled for completion by August 6, 2025, with performance originating from AmerisourceBergen's corporate...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $14,917.09 for RINVOQ ER 30 MG Tablet (UU 30s) by the Defense Logistics Agency Medical Supply Chain. The contract, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizes firm fixed pricing and is classified as a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for RINVOQ ER 45 mg tablets (28-count units) with a ceiling value of $74,205.29. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made competitively without set-aside designation, reflecting...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB25FHXVFDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 3, 2025, valued at $91,328.55 for RINVOQ ER 15 mg tablets (30-count units) under a firm fixed price contract type. The award, issued by the Defense Logistics Agency (DLA), was competitively awarded with no set-aside designation and has an ultimate completion date of September 4, 2025. This delivery order serves as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a prime contract value of $999,999,999.00 and extends through December 2026. The delivery order supports the DLA's pharmaceutical supply chain mission, which provides medications and medical supplies to Defense Health Agency customers, the U.S. Coast Guard, and other federal healthcare systems. RINVOQ ER is a rheumatoid arthritis treatment, reflecting AmerisourceBergen's role as a critical vendor for specialty pharmaceuticals across multiple therapeutic domains. The SPE2DX prime contract represents a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of brand-name and generic medications, vaccines, syringes, and other medical commodities to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $91.3k | 9/3/25 |